INTRODUCTION AND OBJECTIVES:
Kidney cancer is the 9 th most common cancer and accounts yearly for >14,000 American deaths. Papillary RCC (pRCC) is the second most common subtype (10-15% of human tumors compared to >70% for clear cell RCC) and is divided into two histological variants (I and II) . While mutations/amplifications in MET are more prevalent in type I pRCC, MET alterations are associated with more advanced type II pRCC tumors. Until now, no human relevant pRCC mouse models have existed. The PTEN-AKT pathway is disrupted in w28% of human pRCC tumors, but neither PTEN loss nor MET activation alone is sufficient to drive kidney tumor development in mice. Sleeping Beauty(SB11) transposon mutagenesis has been a powerful tool to drive cancer gene discovery in mice for other cancers. We hypothesized that SB11 transposon mutagenesis combined with Pten loss and MET activation would drive pRCC tumorigenesis.
METHODS: Using homologous recombination, we generated mice harboring a Cre-dependent constitutively active Met (Met M1248T ), a recurrent mutation in pRCC. We validated constitutive MET activation by Western Blot and RPPA and tissue specificity of Pepck-Cre by crossing to the tdTomato LsL reporter line. Pten loss, MET activation, and transposon mutagenesis was targeted to the kidney using PepckCre. Mice were screened by MRI and evaluated for gross and histological pathology. Histological sections were assessed by an expert pathologist. Tumors have been harvested for transposon site enrichment analysis(DNA) and to molecularly characterize these tumors(RNA).
RESULTS: Kidneys from Met M1248T/wt , Pepck-Cre þ mice have increased MET phosphorylation by Western blot, and increased MET phosphorylation and STAT3 phosphorylation (downstream target) by RPPA. Pepck-Cre is expressed in renal tubular epithelium with some hepatic expression. On MRI, 93% of mice (n[14/15) have suspicious renal lesions by 8 months. All necropsied mice(n[13/13; >8 mo.) have renal lesions, with the majority of mice harboring bilateral multifocal tumors. 98%(n[39/40) of these tumors closely recapitulate the human pRCC histologic subtype (n [ 26; 67% type I), (n[6; 15% type II) and n[7; 18% mixed I and II.
CONCLUSIONS: This is potentially the first clinically relevant genetic mouse model for pRCC. Transposon site enrichment analysis should enable the discovery of candidate driver genes sufficient for pRCC oncogenesis, experiments that have previously been impossible. Ongoing molecular analysis and comparison to human transcriptome and genome may provide critical insights into the tumorigenesis and behavior of pRCC relevant to human patients. biological features of patient tumors, providing a platform for biomarker identification and preclinical drug testing. We sought to identify predictors of successful tumor engraftment and evaluate the prognostic value of engraftment in patients with RCC using a robust murine PDX platform.
METHODS: 1,200 specimens derived from nephrectomy, thrombectomy, metastasectomy, or biopsy were orthotopically (renally) implanted into NOD/SCID mice between 2008-2018. Non-RCC pathology was excluded. Stable engraftment was defined by successful passage of tumor tissue at least twice with histologic confirmation. Clinicopathologic characteristics were stratified by engraftment status, and multivariate (MVA) logistic regression was used to identify predictors of engraftment. Kaplan-Meier and Cox regression analyses were used to assess the prognostic value of engraftment on patient overall (OS) and disease-free (DFS) survival.
RESULTS: 1,003 independent PDX lines derived from 770 RCC patients were included. 157 (15.6%) lines successfully engrafted and exhibited higher tumor grade, stage, size, and presence of sarcomatoid or rhabdoid components. Whole exome sequencing was performed on 230 PDX lines. On MVA, sarcomatoid (OR 5.71, p<0.001), rhabdoid (OR 2.79, p[0.046) , and advanced stage (OR 1.72, p[0.049) were significant predictors for engraftment, while high grade and metastatic tumor source were significant only on UVA. Engraftment was associated with poor OS (HR 2.11, p<0.001) and DFS (HR 1.85, p[0.020) in patients after controlling for sarcomatoid, rhabdoid, grade, stage, and age on MVA and reflected in Kaplan-Meier analysis ( Figure) .
CONCLUSIONS: Aggressive RCC biology correlates with successful engraftment in PDX models. Engraftment remains independently predictive of OS and DFS even after controlling for adverse pathologic features. Engraftment in mice may illuminate aspects of tumor biology not captured by clinicopathologic variables and provide insight into novel determinants of tumor aggressiveness and metastasis. Efforts are underway to elucidate genomic drivers of engraftment.
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Kassem Faraj*, Kyle Rose, Melissa Stanton, Thai Ho, Alan Bryce, Douglas Lake, Phoenix, AZ; John Copland, Jacksonville, FL; Erik Castle, Phoenix, AZ INTRODUCTION AND OBJECTIVES: Sarcomatoid features are present in about 5% of renal cell carcinoma (RCC) cases and have significant clinical implications, as patients are more likely to succumb to metastatic disease and experience dismal survival outcomes. The molecular behavior of sarcomatoid RCC (sRCC) is not fully understood, but previous reports have described a high prevalence of p53 mutations/overexpression, high proliferative capability, and expression of membrane receptors that influence cell growth. Patient-derived xenografts (PDX) are the most accurate models available to study tumor behavior. We describe our experience in using such a model to better characterize a case of chromophobe sRCC.
METHODS: After IRB approval, a PDX was generated from a patient with metastatic chromophobe sRCC by implanting tumor tissue
